XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and Other Agreements - Incyte Corporation (Details)
 3 Months Ended 7 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 57 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jul. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2017
USD ($)
performanceObligation
Dec. 31, 2018
USD ($)
Sep. 30, 2022
USD ($)
Collaboration And Other Agreements [Line Items]                    
Revenues $ 41,734,000 $ 15,662,000   $ 78,842,000 $ 63,300,000          
Deferred revenue, current 7,085,000     7,085,000   $ 20,646,000       $ 7,085,000
Deferred revenue, net of current portion 5,084,000     5,084,000   0       5,084,000
Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment               $ 150,000,000    
Potential commercial milestone payments under agreement               330,000,000    
Potential development and regulatory milestone payments under agreement               435,000,000    
Development and regulatory milestones recognized         15,000,000         100,000,000
Collaborative agreement transaction price               $ 154,000,000    
Variable consideration recognized                 $ 4,000,000  
Number of performance obligations | performanceObligation               2    
I-Mab | I-Mab Biopharma Collaboration and License Agreement                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment             $ 15,000,000      
Revenues 3,800,000 5,500,000   4,500,000 7,900,000          
Deferred revenue 0     0   4,500,000       0
Development and regulatory milestones recognized       5,000,000   $ 5,000,000        
Minimum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)               15.00%    
Maximum | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)               24.00%    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                    
Collaboration And Other Agreements [Line Items]                    
Revenues               $ 150,000,000    
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities                    
Collaboration And Other Agreements [Line Items]                    
Revenues 30,000,000 0   30,000,000            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                    
Collaboration And Other Agreements [Line Items]                    
Revenues 100,000 200,000   600,000 1,000,000          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement                    
Collaboration And Other Agreements [Line Items]                    
Revenues 0 1,400,000   300,000 $ 7,400,000          
RevenuesFromCMOAgreementsMember | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment     $ 10,000,000              
Annual Fixed Payments 14,400,000     14,400,000           14,400,000
Revenues   $ 1,100,000   5,100,000            
Deferred revenue 9,500,000     9,500,000           9,500,000
Deferred revenue, current 4,400,000     4,400,000           4,400,000
Deferred revenue, net of current portion 5,100,000     5,100,000           5,100,000
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                    
Collaboration And Other Agreements [Line Items]                    
Annual Fixed Payments 19,500,000     19,500,000           19,500,000
Additional Payments $ 5,100,000     $ 5,100,000           $ 5,100,000